A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
AstraZeneca
AstraZeneca
AstraZeneca
AstraZeneca
AstraZeneca
AstraZeneca
AstraZeneca
AstraZeneca
NeoTX Therapeutics Ltd.
Eli Lilly and Company
AstraZeneca
AstraZeneca
AstraZeneca
AstraZeneca
MultiVir, Inc.
AstraZeneca
Pharmacyclics LLC.